Phase 3 Readout
NVO: Phase 3 Topline: ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute M
December 14, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 14, 2026
- Company
- Novo Nordisk A/S (NVO)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute M
- Company
- Novo Nordisk A/S (NVO)
- Indication
- Cardiovascular Risk; Acute Myocardial Infarction (AMI)